Adrian Woolfson

A biotech leader and physician-scientist, he is the Co-founder and CEO of Genyro, a San Diego biotech pioneering AI-guided genome design. He obtained his medical degree at Oxford University, and a PhD from Cambridge University where he worked with Nobel laureate César Milstein at the MRC Laboratory of Molecular Biology. His career includes serving as Executive Vice President and Head of R&D at Nasdaq listed SGMO, senior executive roles at BMS and Pfizer, and co-founding the KKR-backed gene therapy biotech Replay. A regular Opinions contributor to The Wall Street Journal and Science, he bridges high-level drug development in genome engineering and immuno-oncology with visionary leadership in the global life sciences ecosystem. His critically acclaimed book On the Future of Species, addressing the convergence of AI-driven genome design and construction was published in 2026, and has been translated into multiple languages.